Repeatable process for extracting health data from HL7 CDA documents.

Objective: This study aims to address the gap in the literature on converting real-world Clinical Document Architecture (CDA) data into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM), focusing on the initial steps preceding the mapping phase. We highlight the importance of a repeatable Extract-Transform-Load (ETL) pipeline for health data extraction from HL7 CDA documents in Estonia for research purposes.

Methods: We developed a repeatable ETL pipeline to facilitate the extraction, cleaning, and restructuring of health data from CDA documents to OMOP CDM, ensuring a high-quality and structured data format.

Analytical and clinical performance of eight Simoa and Lumipulse assays for automated measurement of plasma p-tau181 and p-tau217.

Background: Among the Alzheimer's disease (AD) biomarkers measured in blood, phosphorylated forms of tau (p-tau) have been shown to exhibit a particularly high diagnostic potential. Here, we performed a comprehensive method comparison study, followed by evaluation of the diagnostic performance of eight recent plasma p-tau immunoassays targeting different tau phosphorylation sites, different tau fragments, and that are measured by two distinct platforms.

Methods: We enrolled a cohort of 40 patients with AD at the stage of dementia (AD-dem) characterized by positive CSF A + T + profile, and a control group of 40 cognitively healthy participants (Control), to conduct a comprehensive method comparison for three plasma p-tau181 and five plasma p-tau217 assays run on the Simoa HD-X™ or Lumipulse G600II/G1200 platforms.

Gastric Cancer Risk among Immigrants and Socioeconomic Groups in the Netherlands.

Background: Identification of groups at a high risk of gastric cancer could facilitate targeted screening in countries with a low gastric cancer incidence. Our aim was to identify such high-risk groups based on individual-level population data on migration history and socioeconomic status (SES) in the Netherlands.

Methods: In this retrospective cohort study, patient data from the Netherlands Cancer Registry were linked to demographic data of Statistics Netherlands in the period 2010 to 2022.

Immune biomarkers and secondary hemophagocytic lymphohistiocytosis: a scoping review protocol.

Objective: The objective of this review is to identify immunological pathways and markers of severity of illness associated with clinical outcomes that may represent potential therapeutic targets in the management of secondary hemophagocytic lymphohistiocytosis.

Introduction: A broad range of immunomodulatory therapies is used to manage hemophagocytic lymphohistiocytosis, however, the supporting evidence for these therapies is scarce. Identifying patients likely to experience more severe disease or die is currently extremely difficult, if not impossible.

The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.

Background: Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer's disease (AD) pathology. Multiple p-tau biomarkers on several analytical platforms are poised for clinical use. The Alzheimer's Association Global Biomarker Standardisation Consortium plasma phospho-tau Round Robin study engaged assay developers in a blinded case-control study on plasma p-tau, aiming to learn which assays provide the largest fold-changes in AD compared to non-AD, have the strongest relationship between plasma and cerebrospinal fluid (CSF), and show the most consistent relationships between methods (commutability) in measuring both patient samples and candidate reference materials (CRM).